This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Reproducibility Study of Over Active Bladder Symptom Score [OABSS] (RESORT)

This study has been completed.
Astellas Pharma China, Inc.
Information provided by:
Astellas Pharma Inc Identifier:
First received: May 11, 2009
Last updated: March 13, 2011
Last verified: March 2011
The purpose of this study is to evaluate the reproducibility of over active bladder symptom score (OABSS) in Asian countries.

Overactive Bladder

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Reproducibility Study of OABSS and Its Response to Treatment - Part 1: Reproducibility -

Resource links provided by NLM:

Further study details as provided by Astellas Pharma Inc:

Primary Outcome Measures:
  • OABSS [ Time Frame: Weeks of 0 and 2 ]

Secondary Outcome Measures:
  • 3-day micturition diary [ Time Frame: 2 times in 2-week interval ]

Enrollment: 50
Study Start Date: January 2009
Study Completion Date: May 2009
Primary Completion Date: May 2009 (Final data collection date for primary outcome measure)


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Symptomatic OAB patients having urgency episodes

Inclusion Criteria:

  • Symptoms OAB for 3 months or longer
  • At least 1 urgency episode in last 3 days
  • Symptoms of OAB as verified by the screening 3-day bladder diary, defined by:

    • Number of micturition ≥8 times/day
    • Number of urgency episode in 3 days ≥1

Exclusion Criteria:

  • Indwelling catheters or practicing intermittent self-catheterization
  • Symptomatic urinary tract infection, chronic inflammation
  • Diabetic neuropathy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00901251

Beijing, China
Chongqing, China
Shanghai, China
Shenyang, China
Wuhan, China
Sponsors and Collaborators
Astellas Pharma Inc
Astellas Pharma China, Inc.
Study Chair: Use Central Contact Astellas Pharma China, Inc.
  More Information

Responsible Party: Disclosure Director, Astellas Pharma, Inc Identifier: NCT00901251     History of Changes
Other Study ID Numbers: VESOABCN02
Study First Received: May 11, 2009
Last Updated: March 13, 2011

Keywords provided by Astellas Pharma Inc:

Additional relevant MeSH terms:
Urinary Bladder, Overactive
Urinary Bladder Diseases
Urologic Diseases
Lower Urinary Tract Symptoms
Urological Manifestations
Signs and Symptoms processed this record on August 18, 2017